{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:15:52Z","timestamp":1772165752475,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81472861"],"award-info":[{"award-number":["81472861"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Project of Zhejiang Province Science and Technology Plan, China","award":["2014C03048-1"],"award-info":[{"award-number":["2014C03048-1"]}]},{"name":"Medical Science and Technology Project of Zhejiang Province, China","award":["2014KYB219; 2017196976"],"award-info":[{"award-number":["2014KYB219; 2017196976"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Germline\n                      <jats:italic>RET<\/jats:italic>\n                      mutations and variants are involved in development of multiple endocrine neoplasia type 2 (MEN2). The present study investigated a spectrum of\n                      <jats:italic>RET<\/jats:italic>\n                      variants, analyzed genotype-phenotype relationships, and evaluated their effect on the MEN2 phenotype in Han Chinese patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Targeted sequencing detected germline\n                      <jats:italic>RET<\/jats:italic>\n                      variants in 697 individuals, including 245 MEN2, 120 sporadic medullary thyroid cancer (MTC), and 15 pheochromocytoma (PHEO) patients and their 493 relatives. In silico analyses and classifications following ACMG-2015 were performed. Demographic, clinical variant types, and endocrine neoplasia molecular diagnosis records were also analyzed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Nineteen different\n                      <jats:italic>RET<\/jats:italic>\n                      mutations (18 point and 1 del\/ins mutations) in 214 patients with MEN2A (97.7%) or MEN2B (2.3%) were found, of which exon 11\/10 mutations accounted for 79% (169\/214). Nineteen compound mutations were found in 31 patients with MEN2A. Twenty-three variants (18 single and 5 double base substitution\/compound variants) non-classification were also found. Of these, 17 (3 of pathogenic, 10 of uncertain significance, 2 of likely benign and 2 as benign) were found in 31 patients with MTC\/PHEO. The remaining 6 variants (4 of uncertain significance and 2 of likely benign) found in 8 carriers had no evidence of MEN2. The entire cohort showed MEN2A-related PHEO, all occurring in exons 11\/10, particularly at C634. Kaplan-Meier curves showed age-dependent penetration rates of MTC and PHEO, and occurrence rates of PHEO in patients with exon 11 mutations were all higher than those within exon 10; these bilateral PHEO were always associated with exon 11 mutations (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). While patient offspring had PHEO, parents with MEN2A had none, the frequency was approximately 10%. Interestingly, at least 6.8% of families were adoptive. Also, 3 non-hotspot\n                      <jats:italic>RET<\/jats:italic>\n                      variants (R114H, T278N, and D489N) appeared with high frequency. Conversely, polymorphism S836S was absent.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      These data are largely consistent with current evidence-based recommendations in the clinical practice guidelines. Diversity of\n                      <jats:italic>RET<\/jats:italic>\n                      variants or carriers may involve a different natural disease course. Further large-scale targeted sequencing studies will serve as an accurate and cost-effective approach to investigating MEN2 genotype-phenotype correlations for discovery of rare or unknown variants of\n                      <jats:italic>RET<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-021-08116-9","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T13:03:59Z","timestamp":1617800639000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Spectrum of Germline RET variants identified by targeted sequencing and associated Multiple Endocrine Neoplasia type 2 susceptibility in China"],"prefix":"10.1186","volume":"21","author":[{"given":"Xiao-Ping","family":"Qi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Qiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu-Dong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bi-Jun","family":"Lian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Lie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Hui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"issue":"6","key":"8116_CR1","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","volume":"25","author":"SA Wells Jr","year":"2015","unstructured":"Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567\u2013610. https:\/\/doi.org\/10.1089\/thy.2014.0335.","journal-title":"Thyroid."},{"issue":"9","key":"8116_CR2","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1093\/hmg\/ddw057","volume":"25","author":"J Smith","year":"2016","unstructured":"Smith J, Read ML, Hoffman J, Brown R, Bradshaw B, Campbell C, et al. Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression. Hum Mol Genet. 2016;25(9):1836\u201345. https:\/\/doi.org\/10.1093\/hmg\/ddw057.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"8116_CR3","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/humu.23378","volume":"39","author":"M Sponziello","year":"2018","unstructured":"Sponziello M, Benvenuti S, Gentile A, Pecce V, Rosignolo F, Virz\u00ec AR, et al. Whole exome sequencing identifies a germline MET mutation in two siblings with hereditary wild-type RET medullary thyroid cancer. Hum Mutat. 2018;39(3):371\u20137. https:\/\/doi.org\/10.1002\/humu.23378.","journal-title":"Hum Mutat"},{"issue":"2","key":"8116_CR4","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1210\/jc.2011-2046","volume":"97","author":"R Elisei","year":"2012","unstructured":"Elisei R, Romei C, Renzini G, Bottici V, Cosci B, Molinaro E, et al. The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center. J Clin Endocrinol Metab. 2012;97(2):426\u201335. https:\/\/doi.org\/10.1210\/jc.2011-2046.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"8116_CR5","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1530\/ERC-17-0488","volume":"25","author":"S Moodley","year":"2018","unstructured":"Moodley S, Weber F, Mulligan LM. The evolving clinical, genetic and therapeutic landscape of multiple endocrine neoplasia type 2. Endocr Relat Cancer. 2018;25(2):E1\u20134. https:\/\/doi.org\/10.1530\/ERC-17-0488.","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"8116_CR6","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s12020-020-02232-5","volume":"68","author":"A Machens","year":"2020","unstructured":"Machens A, Elwerr M, Lorenz K, Weber F, Dralle H. 100-year evolution of precision medicine and surgery for multiple endocrine neoplasia type 2A. Endocrine. 2020;68(2):368\u201376. https:\/\/doi.org\/10.1007\/s12020-020-02232-5.","journal-title":"Endocrine."},{"issue":"10","key":"8116_CR7","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1089\/thy.2018.0385","volume":"29","author":"XP Qi","year":"2019","unstructured":"Qi XP, Jin BY, Li PF, Wang S, Zhao YH, Cao ZL, et al. RET S409Y Germline mutation and associated medullary thyroid carcinoma. Thyroid. 2019;29(10):1447\u201356. https:\/\/doi.org\/10.1089\/thy.2018.0385.","journal-title":"Thyroid."},{"issue":"3","key":"8116_CR8","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1089\/thy.2017.0200","volume":"28","author":"S Chen","year":"2018","unstructured":"Chen S, Li S, Zhang J, Zhang L, Chen Y, Wang L, et al. Preimplantation genetic diagnosis of multiple endocrine Neoplasia type 2A using informative markers identified by targeted sequencing. Thyroid. 2018;28(3):281\u20137. https:\/\/doi.org\/10.1089\/thy.2017.0200.","journal-title":"Thyroid."},{"key":"8116_CR9","doi-asserted-by":"publisher","first-page":"543246","DOI":"10.3389\/fendo.2020.543246","volume":"11","author":"SY Li","year":"2020","unstructured":"Li SY, Ding YQ, Si YL, Ye MJ, Xu CM, Qi XP. 5P Strategies for Management of Multiple Endocrine Neoplasia Type 2: A Paradigm of Precision Medicine. Front Endocrinol (Lausanne). 2020;11:543246.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"8116_CR10","unstructured":"The University of Utah, Department of Pathology, MEN 2 Database. Available at www.arup.utah.edu\/database\/men2\/MEN2_display.php (accessed Jan 2020) ."},{"issue":"19","key":"8116_CR11","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1001\/jama.1996.03540190047028","volume":"276","author":"C Eng","year":"1996","unstructured":"Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel R, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine Neoplasia type 2: international RET mutation consortium analysis. JAMA. 1996;276(19):1575\u20139. https:\/\/doi.org\/10.1001\/jama.1996.03540190047028.","journal-title":"JAMA."},{"issue":"1","key":"8116_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/humu.21385","volume":"32","author":"K Frank-Raue","year":"2011","unstructured":"Frank-Raue K, Rybicki LA, Erlic Z, Schweizer H, Winter A, Milos I, et al. Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. Hum Mutat. 2011;32(1):51\u20138. https:\/\/doi.org\/10.1002\/humu.21385.","journal-title":"Hum Mutat"},{"issue":"12","key":"8116_CR13","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1089\/thy.2012.0134","volume":"22","author":"XP Qi","year":"2012","unstructured":"Qi XP, Chen XL, Ma JM, Du ZF, Fei J, Yang CP, et al. RET proto-oncogene genetic screening of families with multiple endocrine neoplasia type 2 optimizes diagnostic and clinical management in China. Thyroid. 2012;22(12):1257\u201365. https:\/\/doi.org\/10.1089\/thy.2012.0134.","journal-title":"Thyroid."},{"issue":"9","key":"8116_CR14","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3390\/genes10090698","volume":"10","author":"R Elisei","year":"2019","unstructured":"Elisei R, Tacito A, Ramone T, Ciampi R, Bottici V, Cappagli V, et al. Twenty-five years experience on RET genetic screening on hereditary MTC: an update on the prevalence of Germline RET mutations. Genes (Basel). 2019;10(9):698. https:\/\/doi.org\/10.3390\/genes10090698.","journal-title":"Genes (Basel)"},{"issue":"3","key":"8116_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1530\/EJE-12-0919","volume":"168","author":"A Machens","year":"2013","unstructured":"Machens A, Lorenz K, Sekulla C, H\u00f6ppner W, Frank-Raue K, Raue F, et al. Molecular epidemiology of multiple endocrine neoplasia 2: implications for RET screening in the new millenium. Eur J Endocrinol. 2013;168(3):307\u201314. https:\/\/doi.org\/10.1530\/EJE-12-0919.","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"8116_CR16","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1089\/thy.2016.0399","volume":"27","author":"M Lebeault","year":"2017","unstructured":"Lebeault M, Pinson S, Guillaud-Bataille M, Gimenez-Roqueplo AP, Carrie A, Barbu V, et al. Nationwide French study of RET variants detected from 2003 to 2013 suggests a possible influence of polymorphisms as modifiers. Thyroid. 2017;27(12):1511\u201322. https:\/\/doi.org\/10.1089\/thy.2016.0399.","journal-title":"Thyroid."},{"issue":"3","key":"8116_CR17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1530\/EC-18-0506","volume":"8","author":"MBM Rui","year":"2019","unstructured":"Rui MBM, Camacho CP, Assumpcao LV, Bufalo NE, Maia AL. Genotype and phenotype landscape of MEN2 in 554 medullary thyroid cancer patients: the BrasMEN study. Endocr Connect. 2019;8(3):289\u201398.","journal-title":"Endocr Connect"},{"issue":"2","key":"8116_CR18","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1530\/EJE-10-0333","volume":"163","author":"C Romei","year":"2010","unstructured":"Romei C, Mariotti S, Fugazzola L, Taccaliti A, Pacini F, Opocher G, et al. Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. Eur J Endocrinol. 2010;163(2):301\u20138. https:\/\/doi.org\/10.1530\/EJE-10-0333.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"8116_CR19","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1159\/000346174","volume":"1","author":"R Elisei","year":"2013","unstructured":"Elisei R, Alevizaki M, Conte-Devolx B, Frank-Raue K, Leite V, Williams GR. 2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer. Eur Thyroid J. 2013;1(4):216\u201331. https:\/\/doi.org\/10.1159\/000346174.","journal-title":"Eur Thyroid J"},{"issue":"2","key":"8116_CR20","doi-asserted-by":"publisher","first-page":"T41","DOI":"10.1530\/ERC-17-0202","volume":"25","author":"A Machens","year":"2018","unstructured":"Machens A, Dralle H. Advances in risk-oriented surgery for multiple endocrine neoplasia type 2. Endocr Relat Cancer. 2018;25(2):T41\u201352. https:\/\/doi.org\/10.1530\/ERC-17-0202.","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"8116_CR21","doi-asserted-by":"publisher","first-page":"4264","DOI":"10.1210\/jc.2019-00516","volume":"104","author":"F Raue","year":"2019","unstructured":"Raue F, Bruckner T, Frank-Raue K. Long-term outcomes and aggressiveness of hereditary medullary thyroid carcinoma: 40 years of experience at one center. J Clin Endocrinol Metab. 2019;104(10):4264\u201372. https:\/\/doi.org\/10.1210\/jc.2019-00516.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"8116_CR22","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1002\/bjs.10856","volume":"105","author":"FP Prete","year":"2018","unstructured":"Prete FP, Abdel-Aziz T, Morkane C, Brain C, Kurzawinski TR. MEN2 in children UK collaborative group. Prophylactic thyroidectomy in children with multiple endocrine neoplasia type 2. Br J Surg. 2018;105(10):1319\u201327. https:\/\/doi.org\/10.1002\/bjs.10856.","journal-title":"Br J Surg"},{"issue":"6","key":"8116_CR23","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/S1470-2045(14)70154-8","volume":"15","author":"F Castinetti","year":"2014","unstructured":"Castinetti F, Qi XP, Walz MK, Maia AL, Sans\u00f3 G, Peczkowska M, et al. Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. Lancet Oncol. 2014;15(6):648\u201355. https:\/\/doi.org\/10.1016\/S1470-2045(14)70154-8.","journal-title":"Lancet Oncol"},{"issue":"3","key":"8116_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S2213-8587(18)30336-X","volume":"7","author":"F Castinetti","year":"2019","unstructured":"Castinetti F, Waguespack SG, Machens A, Uchino S, Hasse-Lazar K, Sanso G, et al. Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. Lancet Diabetes Endocrinol. 2019;7(3):213\u201320. https:\/\/doi.org\/10.1016\/S2213-8587(18)30336-X.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"8116_CR25","doi-asserted-by":"publisher","first-page":"e20353","DOI":"10.1371\/journal.pone.0020353","volume":"6","author":"XP Qi","year":"2011","unstructured":"Qi XP, Ma JM, Du ZF, Ying RB, Fei J, Jin HY, et al. RET Germline mutations identified by exome sequencing in a Chinese multiple endocrine Neoplasia type 2A\/familial medullary thyroid carcinoma family. PLoS One. 2011;6(5):e20353. https:\/\/doi.org\/10.1371\/journal.pone.0020353.","journal-title":"PLoS One"},{"issue":"1","key":"8116_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1530\/ERC-14-0225","volume":"22","author":"J Cai","year":"2015","unstructured":"Cai J, Li L, Ye L, Jiang X, Shen L, Gao Z, et al. Exome sequencing reveals mutant genes with low penetrance involved in MEN2A-associated tumorigenesis. Endocr Relat Cancer. 2015;22(1):23\u201333. https:\/\/doi.org\/10.1530\/ERC-14-0225.","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"8116_CR27","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1530\/EJE-14-0084","volume":"170","author":"DR Siqueira","year":"2014","unstructured":"Siqueira DR, Ceolin L, Ferreira CV, Romitti M, Maia SC, Maciel LM, et al. Role of RET genetic variants in MEN2-associated pheochromocytoma. Eur J Endocrinol. 2014;170(6):821\u20138. https:\/\/doi.org\/10.1530\/EJE-14-0084.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"8116_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13023-015-0231-z","volume":"10","author":"C Colombo","year":"2015","unstructured":"Colombo C, Minna E, Rizzetti MG, Romeo P, Lecis D, Persani L, et al. The modifier role of RET-G691S polymorphism in hereditary medullary thyroid carcinoma: functional characterization and expression\/ penetrance studies. Orphanet J Rare Dis. 2015;10(1):25. https:\/\/doi.org\/10.1186\/s13023-015-0231-z.","journal-title":"Orphanet J Rare Dis"},{"issue":"13","key":"8116_CR29","doi-asserted-by":"publisher","first-page":"6151","DOI":"10.1002\/cam4.2443","volume":"8","author":"V Mishra","year":"2019","unstructured":"Mishra V, Kowtal P, Rane P, Sarin R. Genetic risk association of CDKN1A and RET gene SNPs with medullary thyroid carcinoma: results from the largest MTC cohort and meta-analysis. Cancer Med. 2019;8(13):6151\u201361. https:\/\/doi.org\/10.1002\/cam4.2443.","journal-title":"Cancer Med"},{"issue":"3","key":"8116_CR30","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1210\/jc.2009-1355","volume":"95","author":"RA Toledo","year":"2010","unstructured":"Toledo RA, Wagner SM, Coutinho FL, Louren\u00e7o DM Jr, Azevedo JA, Longuini VC, et al. High penetrance of pheochromocytoma associated with the novel C634Y\/Y791F double germline mutation in the RET protooncogene. J Clin Endocrinol Metab. 2010;95(3):1318\u201327. https:\/\/doi.org\/10.1210\/jc.2009-1355.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"8116_CR31","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/jso.25371","volume":"119","author":"S H\u00f8xbroe Michaelsen","year":"2019","unstructured":"H\u00f8xbroe Michaelsen S, Ornstrup MJ, Poulsen MM, Bennedbaek FN, Gaustadnes M, Rossing M, et al. Long-term follow-up of RET Y791F carriers in Denmark 1994-2017: a National Cohort Study. J Surg Oncol. 2019;119(6):687\u201393. https:\/\/doi.org\/10.1002\/jso.25371.","journal-title":"J Surg Oncol"},{"issue":"4","key":"8116_CR32","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1530\/ERC-17-0452","volume":"25","author":"M Kaczmarek-Ry\u015b","year":"2018","unstructured":"Kaczmarek-Ry\u015b M, Ziemnicka K, P\u0142awski A, Budny B, Michalak M, Hryhorowicz S, et al. Modifying impact of RET gene haplotypes on medullary thyroid carcinoma clinical course. Endocr Relat Cancer. 2018;25(4):421\u201336.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"8116_CR33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1530\/ERC-14-0491","volume":"22","author":"RA Toledo","year":"2015","unstructured":"Toledo RA, Hatakana R, Louren\u00e7o DM Jr, Lindsey SC, Camacho CP, Almeida M, et al. Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility. Endocr Relat Cancer. 2015;22(1):65\u201376. https:\/\/doi.org\/10.1530\/ERC-14-0491.","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"8116_CR34","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1158\/0008-5472.CAN-05-2995","volume":"66","author":"F Lesueur","year":"2006","unstructured":"Lesueur F, Cebrian A, Robledo M, Niccoli-Sire P, Svensson KA, Pinson S, et al. Polymorphisms in RET and its coreceptors and ligands as genetic modifiers of multiple endocrine neoplasia type 2A. Cancer Res. 2006;66(2):1177\u201380. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-2995.","journal-title":"Cancer Res"},{"issue":"12","key":"8116_CR35","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1089\/thy.2008.0139","volume":"18","author":"A Weinhaeusel","year":"2008","unstructured":"Weinhaeusel A, Scheuba C, Lauss M, Kriegner A, Niederle B. The influence of gender, age, and RET polymorphisms on C-cell hyperplasia and medullary thyroid carcinoma. Thyroid. 2008;18(12):1269\u201376. https:\/\/doi.org\/10.1089\/thy.2008.0139.","journal-title":"Thyroid."},{"issue":"10","key":"8116_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1007678","volume":"14","author":"V Pecce","year":"2018","unstructured":"Pecce V, Sponziello M, Damante G, Rosignolo F, Durante C, Lamartina L, et al. A synonymous RET substitution enhances the oncogenic effect of an in-cis missense mutation by increasing constitutive splicing efficiency. PLoS Genet. 2018;14(10):e1007678. https:\/\/doi.org\/10.1371\/journal.pgen.1007678.","journal-title":"PLoS Genet"},{"issue":"8","key":"8116_CR37","doi-asserted-by":"publisher","first-page":"L63","DOI":"10.1530\/ERC-17-0189","volume":"24","author":"F Castinetti","year":"2017","unstructured":"Castinetti F, Maia AL, Peczkowska M, Barontini M, Hasse-Lazar K, Links TP, et al. The penetrance of MEN2 pheochromocytoma is not only determined by RET mutations. Endocr Relat Cancer. 2017;24(8):L63\u20137. https:\/\/doi.org\/10.1530\/ERC-17-0189.","journal-title":"Endocr Relat Cancer"},{"issue":"32","key":"8116_CR38","doi-asserted-by":"publisher","first-page":"33993","DOI":"10.18632\/oncotarget.4992","volume":"6","author":"XP Qi","year":"2015","unstructured":"Qi XP, Zhao JQ, Chen ZG, Cao JL, Ma J. RET mutation p.S891A in a Chinese family with familial medullary thyroid carcinoma and associated cutaneous amyloidosis binding OSMR variant p.G513D. Oncotarget. 2015;6(32):33993\u20134003. https:\/\/doi.org\/10.18632\/oncotarget.4992.","journal-title":"Oncotarget."},{"issue":"1","key":"8116_CR39","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.gene.2012.12.060","volume":"516","author":"XP Qi","year":"2013","unstructured":"Qi XP, Du ZF, Ma JM, Chen XL, Zhang Q, Fei J, et al. Genetic diagnosis of autosomal dominant polycystic kidney disease by targeted capture and next-generation sequencing: utility and limitations. Gene. 2013;516(1):93\u2013100. https:\/\/doi.org\/10.1016\/j.gene.2012.12.060.","journal-title":"Gene."},{"issue":"5","key":"8116_CR40","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405\u201324. https:\/\/doi.org\/10.1038\/gim.2015.30.","journal-title":"Genet Med"},{"issue":"10","key":"8116_CR41","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/gim.2017.37","volume":"19","author":"K Nykamp","year":"2017","unstructured":"Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, et al. Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria. Genetics Med Official J Am Coll Med Genet. 2017;19(10):1105\u201317. https:\/\/doi.org\/10.1038\/gim.2017.37.","journal-title":"Genetics Med Official J Am Coll Med Genet"},{"issue":"5","key":"8116_CR42","first-page":"1","volume":"36","author":"XP Qi","year":"2018","unstructured":"Qi XP, Zhao JQ, Cao ZL, Fu E, Li F. The clinical Spectrum of multiple endocrine Neoplasia type 2A with cutaneous lichen amyloidosis in ethnic Han Chinese. Cancer Investig. 2018;36(5):1\u201311.","journal-title":"Cancer Investig"},{"issue":"2","key":"8116_CR43","first-page":"312","volume":"164","author":"KY Jung","year":"2018","unstructured":"Jung KY, Kim S, Kim MJ, Cho SW, Kim B, Lee YS, et al. Genotypic characteristics and their association with phenotypic characteristics of hereditary medullary thyroid carcinoma in Korea. Surgery (Oxf). 2018;164(2):312\u20138.","journal-title":"Surgery (Oxf)"},{"issue":"4","key":"8116_CR44","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1530\/EJE-14-0817","volume":"172","author":"HL Sarika","year":"2015","unstructured":"Sarika HL, Papathoma A, Garofalaki M, Saltiki K, Pappa T, Pazaitou-Panayiotou K, et al. Genetic screening of patients with medullary thyroid cancer in a referral center in Greece during the past two decades. Eur J Endocrinol. 2015;172(4):501\u20139. https:\/\/doi.org\/10.1530\/EJE-14-0817.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"8116_CR45","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1530\/EJE-16-1021","volume":"176","author":"LL Cunha","year":"2017","unstructured":"Cunha LL, Lindsey SC. Fran?A MIC, Sarika L, Papathoma a, Kunii IS, et al. evidence for the founder effect of RET533 as the common Greek and Brazilian ancestor spreading multiple endocrine neoplasia 2A. Eur J Endocrinol. 2017;176(5):515\u20139. https:\/\/doi.org\/10.1530\/EJE-16-1021.","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"8116_CR46","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1530\/EC-18-0220","volume":"7","author":"XP Qi","year":"2018","unstructured":"Qi XP, Peng JZ, Yang XW, Zao ZL, Yu XH, Fang XD, et al. The RET C611Y mutation causes MEN 2A and associated cutaneous lichen amyloidosis. Endocr Connect. 2018;7(9):998\u20131005. https:\/\/doi.org\/10.1530\/EC-18-0220.","journal-title":"Endocr Connect."},{"issue":"4","key":"8116_CR47","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/SLA.0b013e3182a6f43a","volume":"259","author":"M Brauckhoff","year":"2013","unstructured":"Brauckhoff M, Machens A, Lorenz K, Bjro T, Dralle H. Surgical curability of medullary thyroid Cancer in multiple endocrine Neoplasia 2B a changing perspective. Ann Surg. 2013;259(4):800\u20136.","journal-title":"Ann Surg"},{"key":"8116_CR48","doi-asserted-by":"crossref","unstructured":"Qi XP, Lin GB, Chen B, Li F, Cao ZL, Zheng WH, et al. Multiple Endocrine Neoplasia Type 2b Associated Mixed Medullary and Follicular Thyroid Carcinoma in A Chinese Patient with RET M918T Germline Mutation. Endocr Metab Immune Disord Drug Targets.\u00a02021;21(3):554-560.","DOI":"10.2174\/1871530320666200713092633"},{"issue":"12","key":"8116_CR49","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s12022-017-9487-2","volume":"28","author":"M Sromek","year":"2017","unstructured":"Sromek M, Czetwerty\u0144ska M, Tarasi\u0144ska M, Janiec-Jankowska A, Chechli\u0144ska M. Analysis of newly identified and rare synonymous genetic variants in the RET gene in patients with medullary thyroid carcinoma in polish population. Endocr Pathol. 2017;28(12):198\u2013206. https:\/\/doi.org\/10.1007\/s12022-017-9487-2.","journal-title":"Endocr Pathol"},{"issue":"5","key":"8116_CR50","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1530\/ERC-11-0117","volume":"18","author":"B Cosci","year":"2011","unstructured":"Cosci B, Vivaldi A, Romei C, Gemignani F, Landi S, Ciampi R, et al. In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer. Endocr Relat Cancer. 2011;18(5):603\u201312. https:\/\/doi.org\/10.1530\/ERC-11-0117.","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"8116_CR51","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1530\/ERC-16-0141","volume":"23","author":"MC Martins-Costa","year":"2016","unstructured":"Martins-Costa MC, Cunha LL, Lindsey SC, Camacho CP, Dotto RP, Furuzawa GK, et al. M918V RET mutation causes familial medullary thyroid carcinoma: study of 8 affected kindreds. Endocr Relat Cancer. 2016;23(12):909\u201320. https:\/\/doi.org\/10.1530\/ERC-16-0141.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"8116_CR52","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/(SICI)1098-1004(200001)15:1<122::AID-HUMU41>3.0.CO;2-7","volume":"15","author":"ME S\u00e1ez","year":"2015","unstructured":"S\u00e1ez ME, Ruiz A, Cebri\u00e1n A, Morales F, Robledo M, Anti\u00f1olo G, et al. A new germline mutation, R600Q, within the coding region of RET proto-oncogene: a rare polymorphism or a MEN 2 causing mutation. Hum Mutat. 2015;15(1):122.","journal-title":"Hum Mutat"},{"issue":"9","key":"8116_CR53","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1002\/ajmg.a.37787","volume":"170","author":"V Rossi","year":"2016","unstructured":"Rossi V, Mosconi M, Nozza P, Murgia D, Mattioli G, Ceccherini I, et al. Chronic intestinal pseudo-obstruction in a child harboring a founder Hirschsprung RET mutation. Am J Med Genet A. 2016;170(9):2400\u20133. https:\/\/doi.org\/10.1002\/ajmg.a.37787.","journal-title":"Am J Med Genet A"},{"issue":"6","key":"8116_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010918","volume":"5","author":"BK Cornes","year":"2010","unstructured":"Cornes BK, Tang CS, Leon TYY, Hui KJWS, So MT, Miao X, et al. Haplotype analysis reveals a possible founder effect of RET mutation R114H for Hirschsprung's disease in the Chinese population. PLoS One. 2010;5(6):e10918. https:\/\/doi.org\/10.1371\/journal.pone.0010918.","journal-title":"PLoS One"},{"issue":"5","key":"8116_CR55","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S0929-6646(09)60084-X","volume":"108","author":"CF Chang","year":"2009","unstructured":"Chang CF, Yang WS, Su YN, Wu IL, Chang TC. Mutational Spectrum of multiple endocrine Neoplasia type 2 and sporadic medullary thyroid carcinoma in Taiwan. J Formos Med Assoc. 2009;108(5):402\u20138. https:\/\/doi.org\/10.1016\/S0929-6646(09)60084-X.","journal-title":"J Formos Med Assoc"},{"issue":"2","key":"8116_CR56","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00383-012-3196-1","volume":"29","author":"K Ishii","year":"2013","unstructured":"Ishii K, Doi T, Inoue K, Okawada M, Lane GJ, Yamataka A, et al. Correlation between multiple RET mutations and severity of Hirschsprung's disease. Pediatr Surg Int. 2013;29(2):157\u201363. https:\/\/doi.org\/10.1007\/s00383-012-3196-1.","journal-title":"Pediatr Surg Int"},{"issue":"4","key":"8116_CR57","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1365-2265.2009.03757.x","volume":"73","author":"MD Castellone","year":"2010","unstructured":"Castellone MD, Verrienti A, Rao DM, Sponziello S, Fabbro D, Muthu M, et al. A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterization. Clin Endocrinol. 2010;73(4):529\u201334. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03757.x.","journal-title":"Clin Endocrinol"},{"issue":"9","key":"8116_CR58","doi-asserted-by":"publisher","first-page":"E92","DOI":"10.1210\/jc.2010-0375","volume":"95","author":"KM Schulte","year":"2010","unstructured":"Schulte KM, Machens A, Fugazzola L, McGregor A, Diaz-Cano S, Izatt L, et al. The clinical spectrum of multiple endocrine neoplasia type 2a caused by the rare intracellular RET mutation S891A. J Clin Endocrinol Metab. 2010;95(9):E92\u20137. https:\/\/doi.org\/10.1210\/jc.2010-0375.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"8116_CR59","first-page":"233","volume":"60","author":"I Schuffenecker","year":"1997","unstructured":"Schuffenecker I, Ginet N, Goldgar D, Eng C, Chambe B, Boneu A, et al. Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma. Le Groupe d'Etude des Tumeurs a Calcitonine. Am J Hum Genet. 1997;60(1):233\u20137.","journal-title":"Am J Hum Genet"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08116-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-021-08116-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08116-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T13:06:11Z","timestamp":1617800771000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08116-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8116"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08116-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-531062\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,7]]},"assertion":[{"value":"18 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was approved by the Ethics Committee of the 903rd PLA Hospital and informed consent was obtained from all individual participants included in the study. All procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have approved the manuscript and agree with the publication in BMC Cancer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"369"}}